Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Educational Report
  • Published:

Acute Leukemias

Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000

Leukemia volume 24, pages 265–284 (2010)Cite this article

Abstract

Between 1981 and 2000, 6609 children (<18 years of age) were treated in five consecutive trials of the Berlin–Frankfurt–Münster (BFM) study group for childhood acute lymphoblastic leukemia (ALL). Patients were treated in up to 82 centers in Germany, Austria and Switzerland. Probability of 10-year event-free survival (EFS) (survival) improved from 65% (77%) in study ALL-BFM 81 to 78% (85%) in ALL-BFM 95. In parallel to relapse reduction, major efforts focused on reducing acute and late toxicity through advanced risk adaptation of treatment. The major findings derived from these ALL-BFM trials were as follows: (1) preventive cranial radiotherapy could be safely reduced to 12 Gy in T-ALL and high-risk (HR) ALL patients, and eliminated in non- HR non-T-ALL patients, if it was replaced by high-dose and intrathecal (IT) MTX; (2) omission of delayed re-intensification severely impaired outcome of low-risk patients; (3) 6-month-less maintenance therapy caused an increase in systemic relapses; (4) slow response to an initial 7-day prednisone window was identified as adverse prognostic factor; (5) condensed induction therapy resulted in significant improvement of outcome; (6) the daunorubicin dose in induction could be safely reduced in low-risk patients and (7) intensification of consolidation/re-intensification treatment led to considerable improvement of outcome in HR patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Riehm H, Gadner H, Welte K . Die West-Berliner Studie zur Behandlung der akuten lymphoblastischen Leukämie des Kindes—Erfahrungsbericht nach 6 Jahren [The west-berlin therapy study of acute lymphoblastic leukemia in childhood—report after 6 years]. Klin Padiatr 1977; 189: 89–102.

    CAS  Google Scholar 

  2. Riehm H, Gadner H, Henze G, Langermann HJ, Odenwald E . The Berlin childhood acute lymphoblastic leukemia therapy study, 1970–1976. Am J Pediatr Hematol Oncol 1980; 2: 299–305.

    Google Scholar 

  3. Hustu HO, Aur RJ, Verzosa MS, Simone JV, Pinkel D . Prevention of central nervous system leukemia by irradiation. Cancer 1973; 32: 585–597.

    CAS  Google Scholar 

  4. Henze G, Langermann HJ, Bramswig J, Breu H, Gadner H, Schellong G et al. Ergebnisse der Studie BFM 76/79 zur Behandlung der akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen [Results of study BFM 76/79 for treatment of acute lymphoblastic leukemia in childhood and adolescence]. Klin Padiatr 1981; 193: 145–154.

    CAS  Google Scholar 

  5. Henze G, Langermann HJ, Fengler R, Brandeis M, Evers KG, Gadner H et al. Therapiestudie BFM 79/81 zur Behandlung der akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen: intensivierte Reinduktionstherapie fur Patientengruppen mit unterschiedlichem Rezidivrisiko [Acute lymphoblastic leukemia therapy study BFM 79/81 in children and adolescents: intensified reinduction therapy for patients with different risk for relapse]. Klin Padiatr 1982; 194: 195–203.

    CAS  Google Scholar 

  6. Riehm H, Gadner H, Henze G, Kornhuber B, Langermann HJ, Müller-Weihrich S et al. Acute lymphoblastic leukemia: treatment results in three BFM studies (1970–1981). In: Murphy SB, Gilbert JR (eds). Leukemia Research: Advances in Cell Biology and Treatment. Elsevier Science Publishing: Amsterdam, 1983, pp 251–263.

    Google Scholar 

  7. Riehm H, Feickert HJ, Schrappe M, Henze G, Schellong G . Therapy results in five ALL-BFM studies since 1970: implications of risk factors for prognosis. Haematol Blood Transfus 1987; 30: 139–146.

    CAS  Google Scholar 

  8. Henze G, Langermann HJ, Kaufmann U, Ludwig R, Schellong G, Stollmann B et al. Thymic involvement and initial white blood count in childhood acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol 1981; 3: 369–376.

    CAS  Google Scholar 

  9. Gaynon PS, Bleyer WA, Steinherz PG, Finklestein JZ, Littman PS, Miller DR et al. Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features. Report of Children's Cancer Study Group Study CCG-193P. Am J Pediatr Hematol Oncol 1988; 10: 42–50.

    CAS  Google Scholar 

  10. Tubergen DG, Gilchrist GS, O'Brien RT, Coccia PF, Sather HN, Waskerwitz MJ et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. J Clin Oncol 1993; 11: 527–537.

    CAS  Google Scholar 

  11. Riehm H, Gadner H, Henze G, Kornhuber B, Lampert F, Niethammer D et al. Results and significance of six randomized trials in four consecutive ALL-BFM studies. Haematol Blood Transfus 1990; 33: 439–450.

    CAS  Google Scholar 

  12. Langermann HJ, Henze G, Wulf M, Riehm H . Abschatzung der Tumorzellmasse bei der akuten lymphoblastischen Leukämie im Kindesalter: prognostische Bedeutung und praktische Anwendung [Estimation of tumor cell mass in childhood acute lymphoblastic leukemia: prognostic significance and practical application]. Klin Padiatr 1982; 194: 209–213.

    CAS  Google Scholar 

  13. Schrappe M, Beck J, Brandeis WE, Feickert HJ, Gadner H, Graf N et al. Die Behandlung der akuten lymphoblastischen Leukamie im Kindes- und Jugendalter: Ergebnisse der multizentrischen Therapiestudie ALL-BFM 81 [Treatment of acute lymphoblastic leukemia in childhood and adolescence: results of the multicenter therapy study ALL-BFM 81]. Klin Padiatr 1987; 199: 133–150.

    CAS  Google Scholar 

  14. Riehm H, Reiter A, Schrappe M, Berthold F, Dopfer R, Gerein V et al. Die Corticosteroid-abhängige Dezimierung der Leukämiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BFM 83) [The in vivo response on corticosteroid therapy as an additional prognostic factor in childhood acute lymphoblastic leukemia (therapy study ALL-BFM 83)]. Klin Padiatr 1986; 199: 151–160.

    Google Scholar 

  15. Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S, Henze G et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84: 3122–3133.

    CAS  Google Scholar 

  16. Schrappe M, Reiter A, Henze G, Niemeyer C, Bode U, Kuhl J et al. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials. Klin Padiatr 1998; 210: 192–199.

    CAS  Google Scholar 

  17. Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German–Austrian–Swiss ALL-BFM Study Group. Blood 2000; 95: 3310–3322.

    CAS  Google Scholar 

  18. Bührer C, Hartmann R, Fengler R, Rath B, Schrappe M, Janka-Schaub G et al. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin–Frankfurt–Munster Relapse Study Group. J Clin Oncol 1996; 14: 2812–2817.

    Google Scholar 

  19. Welte K, Reiter A, Mempel K, Pfetsch M, Schwab G, Schrappe M et al. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin–Frankfurt–Munster Study Group. Blood 1996; 87: 3143–3150.

    CAS  Google Scholar 

  20. van Dongen JJ, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731–1738.

    CAS  Google Scholar 

  21. Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008; 111: 4477–4489.

    Google Scholar 

  22. Conter V, Valsecchi MG, Silvestri D, Campbell M, Dibar E, Magyarosy E et al. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. Lancet 2007; 369: 123–131.

    CAS  Google Scholar 

  23. Balduzzi A, Valsecchi MG, Uderzo C, De Lorenzo P, Klingebiel T, Peters C et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet 2005; 366: 635–642.

    Google Scholar 

  24. Schrauder A, Reiter A, Gadner H, Niethammer D, Klingebiel T, Kremens B et al. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol 2006; 24: 5742–5749.

    Google Scholar 

  25. Bürger B, Zimmermann M, Mann G, Kühl J, Löning L, Riehm H et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol 2003; 21: 184–188.

    Google Scholar 

  26. Ludwig WD, Rieder H, Bartram CR, Heinze B, Schwartz S, Gassmann W et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. Blood 1998; 92: 1898–1909.

    CAS  Google Scholar 

  27. Harbott J, Ritterbach J, Ludwig WD, Bartram CR, Reiter A, Lampert F . Clinical significance of cytogenetic studies in childhood acute lymphoblastic leukemia: experience of the BFM trials. Recent Results Cancer Res 1993; 131: 123–132.

    CAS  Google Scholar 

  28. Viehmann S, Borkhardt A, Lampert F, Harbott J . Multiplex PCR—a rapid screening method for detection of gene rearrangements in childhood acute lymphoblastic leukemia. Ann Hematol 1999; 78: 157–162.

    CAS  Google Scholar 

  29. Schlieben S, Borkhardt A, Reinisch I, Ritterbach J, Janssen JW, Ratei R et al. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia 1996; 10: 957–963.

    CAS  Google Scholar 

  30. Borkhardt A, Cazzaniga G, Viehmann S, Valsecchi MG, Ludwig WD, Burci L et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin–Frankfurt–Munster Study Group. Blood 1997; 90: 571–577.

    CAS  Google Scholar 

  31. Hiddemann W, Wormann B, Ritter J, Thiel E, Gohde W, Lahme B et al. Frequency and clinical significance of DNA aneuploidy in acute leukemia. Ann N Y Acad Sci 1986; 468: 227–240.

    CAS  Google Scholar 

  32. Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007; 370: 240–250.

    CAS  Google Scholar 

  33. Dördelmann M, Reiter A, Borkhardt A, Ludwig WD, Götz N, Viehmann S et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999; 94: 1209–1217.

    Google Scholar 

  34. Ahlke E, Nowak-Göttl U, Schulze-Westhoff P, Werber G, Borste H, Wurthwein G et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Haematol 1997; 96: 675–681.

    CAS  Google Scholar 

  35. Boos J, Werber G, Ahlke E, Schulze-Westhoff P, Nowak-Göttl U, Wurthwein G et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 1996; 32A: 1544–1550.

    CAS  Google Scholar 

  36. Uderzo C, Balduzzi A, de Lorenzo P, Valsecchi MG, Gadner H, Klingebiel T et al. Prospective study on allogeneic bone marrow transplantation (allo BMT) versus chemotherapy (chemo) for very high-risk (VHR) childhood acute lymphoblastic leukaemia in first complete remission. Bone Marrow Transplant 2001; 28 (Suppl 1): S22–S24.

    Google Scholar 

  37. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  38. Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–170.

    CAS  Google Scholar 

  39. Cox DR . Regression models and life tables. J R Stat Soc 1972; 34: 187.

    Google Scholar 

  40. Kalbfleisch JD, Prentice RL . The Statistical Analysis of Failure Time Data, 1st edn. John Wiley: New York, 1980, pp 163–188.

    Google Scholar 

  41. Gray RJ . A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141–1154.

    Google Scholar 

  42. Schrappe M, Camitta B, Pui CH, Eden T, Gaynon P, Gustafsson G et al. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia 2000; 14: 2193–2194.

    CAS  Google Scholar 

  43. Schrappe M, Reiter A, Riehm H . Prophylaxis and treatment of neoplastic meningeosis in childhood acute lymphoblastic leukemia. J Neurooncol 1998; 38: 159–165.

    CAS  Google Scholar 

  44. Löning L, Zimmermann M, Reiter A, Kaatsch P, Henze G, Riehm H et al. Secondary neoplasms subsequent to Berlin–Frankfurt–Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood 2000; 95: 2770–2775.

    Google Scholar 

  45. Stanulla M, Dynybil C, Bartels DB, Dördelmann M, Löning L, Claviez A et al. The NQO1 C609T polymorphism is associated with risk of secondary malignant neoplasms after treatment for childhood acute lymphoblastic leukemia: a matched-pair analysis from the ALL-BFM study group. Haematologica 2007; 92: 1581–1582.

    Google Scholar 

  46. Stanulla M, Löning L, Welte K, Schrappe M . Secondary brain tumours in children with ALL. Lancet 1999; 354: 1126–1127.

    CAS  Google Scholar 

  47. Schmiegelow K, Al-Modhwahi I, Andersen MK, Behrendtz M, Forestier E, Hasle H et al. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Blood 2009; 113: 6077–6084.

    CAS  Google Scholar 

  48. Hijiya N, Hudson MM, Lensing S, Zacher M, Onciu M, Behm FG et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA 2007; 297: 1207–1215.

    CAS  Google Scholar 

  49. Robison LL, Armstrong GT, Boice JD, Chow EJ, Davies SM, Donaldson SS et al. The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol 2009; 27: 2308–2318.

    Google Scholar 

  50. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009; 360: 2730–2741.

    CAS  Google Scholar 

  51. Krappmann P, Paulides M, Stohr W, Ittner E, Plattig B, Nickel P et al. Almost normal cognitive function in patients during therapy for childhood acute lymphoblastic leukemia without cranial irradiation according to ALL-BFM 95 and COALL 06-97 protocols: results of an Austrian–German multicenter longitudinal study and implications for follow-up. Pediatr Hematol Oncol 2007; 24: 101–109.

    CAS  Google Scholar 

  52. Bürger B, Beier R, Zimmermann M, Beck JD, Reiter A, Schrappe M . Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)—experiences from trial ALL-BFM 95. Pediatr Blood Cancer 2005; 44: 220–225.

    Google Scholar 

  53. Toyoda Y, Manabe A, Tsuchida M, Hanada R, Ikuta K, Okimoto Y et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol 2000; 18: 1508–1516.

    CAS  Google Scholar 

  54. Stanulla M, Schäffeler E, Möricke A, Coulthard SA, Cario G, Schrauder A et al. Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin–Frankfurt–Munster protocols. Blood 2009; 114: 1314–1318.

    CAS  Google Scholar 

  55. Schmiegelow K, Forestier E, Kristinsson J, Soderhall S, Vettenranta K, Weinshilboum R et al. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Leukemia 2009; 23: 557–564.

    CAS  Google Scholar 

  56. Stanulla M, Schäffeler E, Flohr T, Cario G, Schrauder A, Zimmermann M et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 2005; 293: 1485–1489.

    CAS  Google Scholar 

  57. Stanulla M, Schrappe M, Brechlin AM, Zimmermann M, Welte K . Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case–control study. Blood 2000; 95: 1222–1228.

    CAS  Google Scholar 

  58. Stanulla M, Schunemann HJ . Thioguanine versus mercaptopurine in childhood ALL. Lancet 2006; 368: 1304–1306.

    Google Scholar 

  59. Anderer G, Schrappe M, Brechlin AM, Lauten M, Muti P, Welte K et al. Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. Pharmacogenetics 2000; 10: 715–726.

    CAS  Google Scholar 

  60. Arico M, Valsecchi MG, Conter V, Rizzari C, Pession A, Messina C et al. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin–Frankfurt–Muenster protocol II. Blood 2002; 100: 420–426.

    CAS  Google Scholar 

  61. Lange BJ, Bostrom BC, Cherlow JM, Sensel MG, La MK, Rackoff W et al. Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2002; 99: 825–833.

    CAS  Google Scholar 

  62. Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998; 338: 1663–1671.

    CAS  Google Scholar 

  63. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 771–782.

    CAS  Google Scholar 

  64. van der Velden VH, Panzer-Grümayer ER, Cazzaniga G, Flohr T, Sutton R, Schrauder A et al. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia 2007; 21: 706–713.

    CAS  Google Scholar 

  65. Schrappe M, Arico M, Harbott J, Biondi A, Zimmermann M, Conter V et al. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood 1998; 92: 2730–2741.

    CAS  Google Scholar 

  66. Arico M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000; 342: 998–1006.

    CAS  Google Scholar 

  67. Peters C, Schrauder A, Schrappe M, von Stackelberg A, Stary J, Yaniv I et al. Allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia: the BFM/IBFM/EBMT concepts. Bone Marrow Transplant 2005; 35 (Suppl 1): S9–S11.

    Google Scholar 

  68. Cario G, Stanulla M, Fine BM, Teuffel O, Neuhoff NV, Schrauder A et al. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood 2005; 105: 821–826.

    CAS  Google Scholar 

  69. Cario G, Fetz A, Bretscher C, Möricke A, Schrauder A, Stanulla M et al. Initial leukemic gene expression profiles of patients with poor in vivo prednisone response are similar to those of blasts persisting under prednisone treatment in childhood acute lymphoblastic leukemia. Ann Hematol 2008; 87: 709–716.

    CAS  Google Scholar 

  70. Attarbaschi A, Mann G, Panzer-Grümayer R, Röttgers S, Steiner M, Konig M et al. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin–Frankfurt–Munster (ALL-BFM) trials. J Clin Oncol 2008; 26: 3046–3050.

    CAS  Google Scholar 

  71. Beger C, Gerdes K, Lauten M, Tissing WJ, Fernandez-Munoz I, Schrappe M et al. Expression and structural analysis of glucocorticoid receptor isoform gamma in human leukaemia cells using an isoform-specific real-time polymerase chain reaction approach. Br J Haematol 2003; 122: 245–252.

    CAS  Google Scholar 

  72. Lauten M, Beger C, Gerdes K, Asgedom G, Kardinal C, Welte K et al. Expression of heat-shock protein 90 in glucocorticoid-sensitive and -resistant childhood acute lymphoblastic leukaemia. Leukemia 2003; 17: 1551–1556.

    CAS  Google Scholar 

  73. Lauten M, Fernandez-Munoz I, Gerdes K, von Neuhoff N, Welte K, Schlegelberger B et al. Kinetics of the in vivo expression of glucocorticoid receptor splice variants during prednisone treatment in childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer 2009; 52: 459–463.

    Google Scholar 

  74. Lauten M, Schrauder A, Kardinal C, Harbott J, Welte K, Schlegelberger B et al. Unsupervised proteome analysis of human leukaemia cells identifies the valosin-containing protein as a putative marker for glucocorticoid resistance. Leukemia 2006; 20: 820–826.

    CAS  Google Scholar 

  75. Nguyen K, Devidas M, Cheng SC, La M, Raetz EA, Carroll WL et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia 2008; 22: 2142–2150.

    CAS  Google Scholar 

  76. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758–764.

    CAS  Google Scholar 

  77. Rhein P, Scheid S, Ratei R, Hagemeier C, Seeger K, Kirschner-Schwabe R et al. Gene expression shift towards normal B cells, decreased proliferative capacity and distinct surface receptors characterize leukemic blasts persisting during induction therapy in childhood acute lymphoblastic leukemia. Leukemia 2007; 21: 897–905.

    CAS  Google Scholar 

  78. Yang JJ, Cheng C, Yang W, Pei D, Cao X, Fan Y et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 2009; 301: 393–403.

    CAS  Google Scholar 

  79. Staal FJ, Cario G, Cazzaniga G, Haferlach T, Heuser M, Hofmann WK et al. Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks. Leukemia 2006; 20: 1385–1392.

    CAS  Google Scholar 

  80. Biondi A, Valsecchi MG, Seriu T, D'Aniello E, Willemse MJ, Fasching K et al. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. Leukemia 2000; 14: 1939–1943.

    CAS  Google Scholar 

  81. van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grümayer ER et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007; 21: 604–611.

    CAS  Google Scholar 

  82. van der Velden VH, Corral L, Valsecchi MG, Jansen MW, de Lorenzo P, Cazzaniga G et al. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia 2009; 23: 1073–1079.

    CAS  Google Scholar 

Download references

Acknowledgements

Support: This work was supported by grants from the Deutsche Krebshilfe, Bonn, Germany; Deutsche Leukämieforschungshilfe, Bonn, Germany and from the Madeleine-Schickedanz-Kinder-krebsstiftung, Fürth, Germany. We thank the patients and families who participated in this trial, the physicians and nurses of all hospitals for their input in performing this study and the study committee for productive discussions during the development and progress of the trial. We thank N Götz, D Janousek, U Meyer, I Krämer, K Mischke, M Gerzmehle and K Schwermer for data management, and the staff of the reference laboratories for excellent cooperation and expert diagnostics.

Author information

Authors and Affiliations

  1. Department of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany

    A Möricke, A Schrauder, M Stanulla & M Schrappe

  2. Department of Pediatric Hematology and Oncology, Medizinische Hochschule, Hannover, Germany

    M Zimmermann, K Welte, E Odenwald & H Riehm

  3. Department of Pediatric Hematology and Oncology, University Children's Hospital, Giessen, Germany

    A Reiter

  4. Department of Pediatric Hematology and Oncology, Charité, Humboldt University, Berlin, Germany

    G Henze

  5. Department of Pediatrics, St Anna Kinderspital, Vienna, Austria

    H Gadner & G Mann

  6. Department of Hematology, Oncology, and Tumor Immunology, Robert-Rössle-Clinic, HELIOS Medical Center Berlin-Buch, Berlin, Germany

    W D Ludwig

  7. Department of Pediatric Hematology and Oncology, University Children's Hospital, Münster, Germany

    J Ritter

  8. Oncogenetic Laboratory, University Children's Hospital, Giessen, Germany

    J Harbott

  9. Department of Pediatric Hematology and Oncology, University Children's Hospital, Frankfurt, Germany

    T Klingebiel

  10. Department of Pediatric Hematology and Oncology, University Children's Hospital, Jena, Germany

    F Zintl

  11. Department of Pediatric Hematology and Oncology, University Children's Hospital, Freiburg, Germany

    C Niemeyer

  12. Department of Pediatric Hematology and Oncology, University Children's Hospital, Essen, Germany

    B Kremens

  13. Department of Pediatric Hematology and Oncology, University Children's Hospital, Zürich, Switzerland

    F Niggli

  14. Department of Pediatric Hematology and Oncology, University Children's Hospital, Tübingen, Germany

    D Niethammer

Authors
  1. A Möricke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Zimmermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Reiter
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Henze
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Schrauder
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H Gadner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W D Ludwig
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J Ritter
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J Harbott
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G Mann
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. T Klingebiel
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. F Zintl
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. C Niemeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. B Kremens
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. F Niggli
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. D Niethammer
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. K Welte
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. M Stanulla
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. E Odenwald
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. H Riehm
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. M Schrappe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Schrappe.

Additional information

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)

Supplementary information

Appendix

Appendix

Study committee (ALL-BFM 95)

Members of the study committee of the German–Austrian–Swiss ALL-BFM Study Group were as follows (all locations are in Germany, unless otherwise indicated): J Beck, Erlangen; U Bode, Bonn; J Boos, Münster; A Feldges, St Gallen, Switzerland; H Gadner, Wien, Austria; W Havers, Essen; G Henze, Berlin; B Kornhuber, Frankfurt; J Kühl, Würzburg; F Lampert, Gießen; E Maass, Stuttgart; U Mittler, Magdeburg; C Niemeyer, Freiburg; D Niethammer, Tübingen; F Niggli, Zürich, Switzerland; A Reiter, Hannover; H Riehm, Hannover; J Ritter, Münster; M Schrappe, Hannover; C Urban, Graz, Austria; H Wehinger, Kassel; K Welte, Hannover; and F Zintl, Jena.

Participating centers and clinicians

Aachen, Kinderklinik der Medizinisches Fakultät der Rheinisch-Westfälischen Technischen Hochschule (Dr R Mertens); Aarau, Kinderklinik, Hämatologie/Onkologie (Professor Dr R Imbach, Dr E Signer); Augsburg, Kinderklink I des Krankenhauszweckverbandes Augsburg, Hämatologie/Onkologie (Professor P Heidemann); Bad Mergentheim, Caritaskrankenhaus, Kinderklinik (Dr K Rager); Basel, Basler Kinderspital, Onkologie/Hämatologie Poliklinik (Professor Dr P Imbach); Bayreuth, Klinikum Bayreuth, Kinderklinik (Professor Dr GF Wündisch); Berlin, Kinderklinik der Charité, Abteilung Hämatologie/Onkologie (Professor Dr G Henze, Professor Dr G Gaedicke); Berlin, Klinikum Berlin II Buch, Kinderklinik (Dr W Dörffel); Bonn, Zentrum für Kinderheilkunde der Universität Bonn, Abteilung Pädiatrische Hämatologie/Onkologie (Professor Dr U Bode); Braunschweig, Städtisches Krankenhaus Kinderklinik (Dr W Eberl, Professor Dr G Mau); Celle, Allgemeines Krankenhaus, Kinderklinik (Professor Dr H Jacobi); Chemnitz, Klinikum Chemnitz gGmbH, Klinik für Kinder- und Jugendmedizin, Abteilung Hämatologie/Onkologie (Dr K Hofmann); Coburg, Landeskrankenhaus, Kinderklinik (Dr JD Thaben); Cottbus, Carl-Thiem-Klinikum, Kinderklinik, Abteilung Hämatologie/Onkologie (Dr D Möbius); Datteln, Vestische Kinderklinik, Universität Witten/Herdecke (Professor Dr W Andler); Delmenhorst, Städtische Kliniken, Kinderklinik (Dr C Niekrens); Dortmund, Städtische Kliniken, Kinderklinik (Dr H Breu); Dresden, Städtisches Krankenhaus, Dresden-Neustadt, Kinderklinik (Dr V Scharfe); Duisburg, Städtische Kinderklinik (Dr P Zickler); Erfurt, Helios Klinikum Erfurt GmbH, Klinik für Kinderheilkunde (Dr G Weinmann); Erlangen, Klinik für Kinder und Jugendliche der Universität Erlangen-Nürnberg (Professor Dr J-D Beck); Essen, Universitätsklinikum Essen, Kinderklinik, Hämatologie und Onkologie (Professor Dr W Havers, Dr B Kremens); Feldkirch, Landeskrankenhaus, Kinderklinik (Dr G Müller); Frankfurt/Main, Universitäts-Kinderklinik, Klinik für Kinderheilkunde III, Pädiatrische Hämatologie und Onkologie (Professor Dr B Kornhuber); Freiburg, Universitäts-Kinderklinik, Hämatologie u. Onkologie (Professor Dr C Niemeyer); Gießen, Klinikum der Justus-Liebig-Universität, Zentrum für Kinderheilkunde, Abteilung Hämatologie u. Onkologie (Professor Dr A Reiter, Professor Dr F Lampert); Göttingen, Universitäts-Kinderklinik (Professor Dr M Lakomek); Graz, Landeskrankenhaus, Universitäts-Kinderklinik, Abt. für Hämatologie/Onkologie (Professor Dr C Urban); Gummersbach, Kreiskrankenhaus Gummersbach, Kinderklinik, Hämatoonkologie (Dr V Gerein); Halle, Martin-Luther-Universität, Medizinische Fakultät, Zentrum für Kinderheilkunde, Klinik für Kinder und Jugendmedizin (Professor Dr P Exadaktylos, Professor Dr St Burdach); Hannover, Medizinische Hochschule Hannover, Kinderheilkunde IV, Pädiatrische Hämatologie und Onkologie (Professor Dr H Riehm, Professor Dr K Welte); Heidelberg, Universitäts-Kinderklinik, Pädiatrische Onkologie, Hämatologie, und Immunologie (Dr B Selle); Herdecke, Gemeinschaftskrankenhaus, Kinderabteilung (Dr Ch. Tautz); Homburg/Saar, Universitätsklinik für Kinder- und Jugendmedizin, Pädiatrische Hämatologie und Onkologie (Professor Dr N Graf); Innsbruck, Ä. ö. Landeskrankenhaus, Universitäts-Kinderklinik (Dr K Dengg); Jena, Klinikum der Friedrich-Schiller-Universität, Klinik für Kinder- und Jugendmedizin (Professor Dr F Zintl); Kaiserslautern, Westpfalz-Klinikum GmbH, Kinderklinik (Dr FJ Gutwein); Karlsruhe, Städtisches Klinikum Karlsruhe, Kinderklinik (Dr G Nessler, Dr W Dupuis); Kassel, Städtische Kinderklinik (Professor Dr H Wehinger, Dr M Rodehüser); Klagenfurt, A. ö. Krankenhaus des Landes Kärnten, Kinderinterne Abteilung (Dr W Kaulfersch); Koblenz, Städtisches Krankenhaus Kemperhof, Kinderklinik (Professor Dr M Rister); Köln, Klinik für Kinderheilkunde der Universität zu Köln (Professor Dr F Berthold); Kiel, Klinik für Allgemeine Pädiatrie, Universitäts-Kinderklinik (Professor Dr R Schneppenheim, Dr M Suttorp); Köln, Städtisches Kinderkrankenhaus (Dr W Sternschulte); Lausanne, Centre Hospitalier Universitaire Vandois, Département de pédiatrie, Unité d'onco-hematologie (Dr RM Garcia); Leipzig, Universitäts-Kinder- und Poliklinik, Abteilung Hämatologie (Dr M Domula); Leoben, Landeskrankenhaus, Kinderabteilung (Professor Dr I Mutz, Dr R Moser); Linz, Landes-Kinderkrankenhaus (Professor Dr K Schmitt, Dr G Ebetsberger); Linz, A. ö. Krankenhaus der Barmherzigen Schwestern, Kinderabteilung (Dr O Stöllinger); Locarno, Ospedale regionale, Pediatria (Dr L Nobile Buetti); Lübeck, Medizinische Universität zu Lübeck, Klinik für Pädiatrie (Professor Dr P Bucsky); Ludwigshafen, Kinderklinik St Annastift, Pädiatrische Onkologie, Hämatologie und Immunologie (Professor Dr HC Dominick); Luzern, Kantonspital Luzern, Pädiatrische Klinik, Kinderonkologie (Dr U Caflisch); Magdeburg, Otto-von-Guericke-Universität, Medizinische Fakultät, Zentrum für Kinderheilkunde (Professor Dr U Mittler); Mannheim, Klinikum der Stadt Mannheim, Kinderklinik (Dr O Sauer); Marburg, Klinikum der Philipps-Universität, Medizinisches Zentrum für Kinderheilkunde (Dr H Christiansen); Minden, Kinderklinik des Klinikum Minden (Professor Dr W Tillmann); München, Städtisches Krankenhaus München-Schwabing, Kinderklinik der Technischen Universität, Hämatologie/Onkologie (Professor Dr S Müller-Weihrich); München, Kinderpoliklinik der Ludwig-Maximilians-Universität (Professor Dr C Bender-Götze); Münster, Westfälische Wilhelms-Universität, Klinik und Poliklinik für Kinderheilkunde, Pädiatrische Hämatologie und Onkologie (Professor Dr H Jürgens, Professor Dr J Ritter); Nürnberg, Cnopf'sche Kinderklinik, Onkologie (Dr A Jobke); Nürnberg, Stadt Nürnberg-Klinikum Süd, Kinderklinik, (Dr U Schwarzer); Neunkirchen, Gemeinnützige Klinik-Gesellschaft des Landkreises Neunkirchen mbH, Kinderklinik Kohlhof (Professor O Schofer); Rostock, Universitäts-Kinderklinik K1 (Professor Dr G Eggers); Stuttgart, Olga-Hospital, Kinderklinik K1, Pädiatrisches Zentrum, Abteilung Hämatologie/Onkologie (Professor Dr J Treuner); Saarbrücken, Saarbrücker Winterbergkliniken, Gemeinnützige GmbH, Kinderklinik (Dr R Geib); Salzburg, Regional Hospital, Department of Paediatrics (Dr N Jones); Sankt Augustin, Johanniter Kinderklinik für den Rhein-Sieg-Kreis (Dr R Dickerhoff); Schwerin, Klinikum Schwerin, Kinderklinik (Dr D Neubert); Siegen, Deutsches Rotes Kreuz, Kinderklinik (Dr F-J Göbel); Steyr, Landeskrankenhaus, Kinderabteilung (Dr R Ploier); St Gallen, Ostschweizer Kinderspital, Foederatio Medicorum Helveticorum Pädiatrie, spez. Hämatologie (Dr A Feldges, Dr J Greiner); Trier, Krankenanstalt Trier, Mutterhaus der Borromäerinnen, Pädiatrische Abteilung (Professor Dr W Rauh); Tübingen, Universitäts-Kinderklinik, Abteilung Kinderheilkunde I, Hämatologie/Onkologie (Professor Dr D Niethammer, Professor Dr T Klingebiel); Ulm, Universitäts- Kinder- und Poliklinik (Professor Dr K-M Debatin, Professor E Kleihauer); Vechta, St Marienhospital, Kinderabteilung (Dr D Franke); Wien, St Anna Kinderspital (Professor Dr H Gadner, Dr Ch. Peters, Dr G Mann); Wolfsburg, Stadtkrankenhaus, Kinderklinik (Professor Dr J Otte); Würzburg, Universitäts-Kinderklinik (Dr J Kühl); Wilhelmshaven, Reinhard-Nieter-Krankenhaus, Kinderklinik (Professor Dr H-P Krohn); Zürich, Kinderspital Zürich, Universitäts-Kinderklinik (Dr F Niggli).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Möricke, A., Zimmermann, M., Reiter, A. et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 24, 265–284 (2010). https://doi.org/10.1038/leu.2009.257

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2009.257

Keywords

This article is cited by

Search

Advanced search

Quick links